Patients hospitalized for heart failure who have cannabis use disorder (CUD) are significantly more likely to experience ...

New clinical results from multiple studies show coronary heart disease death associated with tobacco use is anticipated to rise up to 40% in the next five years and people with cannabis use disorder ...

For patients with asymptomatic or symptomatic carotid stenosis of 50 percent or greater with a low or intermediate predicted ...

Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration to manufacture ...

Alembic Pharmaceuticals has received USFDA approval to market generic Ticagrelor Tablets, a medication for preventing heart ...

Vadodara: Alembic Pharmaceuticals Limited has announced that the US Food & Drug Administration (USFDA) has given final ...

These heart cells rupture and leak DNA, which sparks a damaging immune response. This breakthrough challenges long-held assumptions and offers fresh strategies for preventing heart failure by calming ...

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

The company's approved ANDA is therapeutically equivalent to AstraZeneca Pharmaceuticals's Brilinta Tablets, 60 mg and 90 mg, it added.

Alembic Pharmaceuticals receives FDA approval for Ticagrelor Tablets 60 mg and 90 mg, therapeutically equivalent to Brilinta.

Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ticagrelor Tablets, ...